With a surge in preclinical investment, fresh news of clinical pipeline progressions, and a new era of therapies pending FDA approvals from Biogen, Eisai, and Denali Therapeutics, 2022 has put neurodegenerative drug development back on the map.
Building on the field's momentum, we are delighted to bring back the 11th Alzheimer's and Parkinson's Drug Development Summit, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery, preclinical, translational, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer's, Parkinson's, and related neurological disorders in 2022 and 2023.
Speakers: Karen He Scientist, Disease Genetics Janssen, Tien Dam Executive Medical Director - Neurodegeneration Development Unit, Head of Movement Disorders Biogen, Cheng Fang Senior Vice President, Research and Development Annovis Bio, Sarah Huntwork-Rodriguez Associate Director, Biomarkers Denali Therapeutics Inc., Dimitrios Kapogiannis Senior Investigator, Chief of Human Neuroscience Section NINDS/NIH, Henri Huttunen Chief Scientific Officer Herantis Pharma Plc, Judith Kelleher-Andersson Chief Executive Officer and President Neuronascent, Sam Jackson Chief Medical Officer Neuron23, Viktoria Kheifets Senior Vice President Alkahest, Jeffrey Kordower Professor and Founding Director, ASU-Banner Neurodegenerative Disease Research Center Rush University Medical Center, Justine Manos Principal Research Scientist II Abbvie Inc., Rouba Kozak Global Biomarker Diagnostic and Neuroscience Lead Novartis AG, Meriel Owen Associate Director, Search and Evaluation Alzheimer's Drug Discovery, Jacob Marcus Director Merck and Co, Luis Miguel Oliveira Senior Associate Director - Research Programs The Michael J. Fox Foundation for Parkinson's Research, Bruce Morimoto Vice President, Drug Development Alto Neuroscience, Ryan Schubert Senior Vice President Translational Medicine and Clinical Strategy ASCENEURON, Andrea Small-Howard President and Chief Science Officer GrowBlox Sciences OTCQB, Ana Cristina Puhl Associate Director Collaborations Pharmaceuticals Inc., Anindya Sen Executive Director Prevail Therapeutics, Milton Werner President and Chief Scientific Officer Inhibikase Therapeutics, Steve Stice Co-Founder and Chief Scientific Officer ArunA Bio, Gregory Stewart Consultant Alcyone Life Sciences, Diane Stephenson Executive Director, Critical Path for Parkinson's Critical Path Institute, Gayle Wittenberg Vice President - Neuroscience Data Science and Digital Health Johnson and Johnson Services, Inc, Jian Yang Associate Vice President, Digital Health Research and Development Eli Lilly and Co., Hiu Zhang Senior Director Eli Lilly and Co.
Schedule:
09:00 - 17:30
| Contact Person: | Erin Thomas |
| Contact Email | info@hansonwade.com |
| Organizer State/Province: (Outside US) | |
| Organizer Country | Data not provided |
| Organizer Phone | +1 617 455 4188 |
| Structural makeup | Data not provided |
| Host Sponsor; Other Sponsors | Hanson Wade |
| Event Site/Venue | Hyatt Centric Fisherman's Wharf San Francisco |
| Event sold out? | No |
| Multiple locations or dates? | No |
| Statistics available for most recent event held in: | NA |
| Average number in event attendance of: | |
| Range: | |
| Number in attendance of: | |
| Range: | |
| total attendance #: | 1000 |
| Target Boundaries | International |
| Is Registration contact information the same as Organizer Contact above? | Yes |
| Web Page | https://go.evvnt.com/1401329-1?pid=5188 |
| Can one register for your CE on your web site? | NA |
| Can registration be made by snail (regular) mail? | Yes |
| Online housing reservations: |
|
| Do you have additional written or AV materials for sale? | No |
| If so, are they available for non-attendees as well as those attending? | NA |
| Is full tuition necessary to ensure registration? | No |
| Will there be shuttle service available? | NA |
| Additional notes: | Brochure: https://go.evvnt.com/1401329-3?pid=5188 |